DISSOLUTION BEHAVIOR OF 17-BETA-ESTRADIOL (E2) FROM POVIDONE COPRECIPITATES - COMPARISON WITH MICROCRYSTALLINE AND MACROCRYSTALLINE E2

被引:8
作者
RESETARITS, DE
CHENG, KC
BOLTON, BA
PRASAD, PN
SHEFTER, E
BATES, TR
机构
[1] SUNY BUFFALO, SCH PHARM, DEPT PHARMACEUT, AMHERST, NY 14260 USA
[2] SUNY BUFFALO, DEPT CHEM, AMHERST, NY 14260 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1016/0378-5173(79)90054-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The dissolution rates of macrocrystalline 17β-estradiol (E2), microcrystalline E2and E2-povidone coprecipitates and physical mixtures varying in weight ratio from 1 : 1 to 1:49 were determined at 37°C. E2 dissolution from the coprecipitates was markedly faster than that from either macro- or microcrystalline forms of the drug and was found to increase with decreasing E2-to-povidone weight ratio. Based on the results of X-ray diffraction, differential scanning calorimetric. Raman spectroicopic, and thermal gravi metric analysis studies, it is concluded that the formation of a more water soluble, high energy state of E2 is responsible for the increased dissolution rate of this natural cstrogen from low weight ratio povidone coprecipitates. These findings suggest that the use of E2-povidone coprecipitates may increase the systemic availability of E2. © 1979.
引用
收藏
页码:113 / 123
页数:11
相关论文
共 16 条
[1]  
Bates T. R., 1970, CURRENT CONCEPTS PHA, P57
[2]   SOLUBILIZING PROPERTIES OF BILE SALT SOLUTIONS 2 - EFFECT OF INORGANIC ELECTROLYTE LIPIDS AND A MIXED BILE SALT SYSTEM ON SOLUBILIZATION OF GLUTETHIMIDE GRISEOFULVIN AND HEXESTROL [J].
BATES, TR ;
GIBALDI, M ;
KANIG, JL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1966, 55 (09) :901-&
[3]   SOLUBILIZING PROPERTIES OF BILE SALT SOLUTIONS .1. EFFECT OF TEMPERATURE AND BILE SALT CONCENTRATION ON SOLUBILIZATION OF GLUTETHIMIDE GRISEOFULVIN AND HEXESTROL [J].
BATES, TR ;
GIBALDI, M ;
KANIG, JL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1966, 55 (02) :191-&
[4]   DETERMINATION OF DRUG POLYMORPHS BY LASER RAMAN-SPECTROSCOPY .1. AMPICILLIN AND GRISEOFULVIN [J].
BELLOWS, JC ;
CHEN, FP ;
PRASAD, PN .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1977, 3 (05) :451-458
[5]  
BOTELLALLUSIA J, 1973, ENDOCRINOLOGY WOMEN, P30
[6]   INTERMEDIATES IN TRANSFORMATION OF ORAL ESTRADIOL [J].
FISHMAN, J ;
GOLDBERG, S ;
ROSENFELD, RS ;
ZUMOFF, B ;
HELLMAN, L ;
GALLAGHER, TF .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1969, 29 (01) :41-+
[7]  
GIBALDI M, 1975, PHARMACOKINETICS, P229
[8]  
Ho N.F.H., 1977, DESIGN BIOPHARMACEUT, P136
[9]  
KRANTZ JC, 1958, PHARMACOLOGIC PRINCI, P1049
[10]  
MARTIN PL, 1972, OBSTET GYNECOL, V39, P771